Patient-Reported Outcome Measures in Takayasu Arteritis: A Systematic Review and Meta-Analysis

Misra, Durga Prasanna; Rathore, Upendra; Patro, Pallavi; Agarwal, Vikas; Sharma, Aman

doi:10.1007/s40744-021-00355-3

Cited by 17 publications

(13 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fewer studies had compared PROMs between active and inactive TAK, or assessed changes in PROMs following the initiation of medical treatment. Despite TAK being way more frequent in Asia, very few studies from Asia had assessed PROMs in TAK [ 29 ].…”

Section: Clinical Assessment Of Disease Activity and Damagementioning

confidence: 99%

“…There does not yet exist a PROM specific to TAK [ 29 ]. Only one study has attempted to develop a TAK-specific PROM by undertaking qualitative interviews of 31 patients with TAK from the USA and Turkey.…”

Section: Clinical Assessment Of Disease Activity and Damagementioning

confidence: 99%

“…The emotional impact of the disease was important during periods of inactive disease [ 30 ]. A TAK-specific PROM that is developed in the future should also consider including these features as well as clinical features of TAK such as claudication and limitation of work capacity due to heart failure [ 29 ]. Clinical features related to TAK that are considered important by patients might differ in different geographical regions.…”

Section: Clinical Assessment Of Disease Activity and Damagementioning

confidence: 99%

“…Clinical features related to TAK that are considered important by patients might differ in different geographical regions. Therefore, these might require reassessment by qualitative research in different patient groups [ 29 ].…”

Section: Clinical Assessment Of Disease Activity and Damagementioning

confidence: 99%

See 3 more Smart Citations

Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis

et al. 2022

View full text Add to dashboard Cite

Takayasu arteritis (TAK) is a less common large vessel vasculitis where histopathology of involved arteries is difficult to access except during open surgical procedures. Assessment of disease activity in TAK, therefore, relies on surrogate measures. Clinical disease activity measures such as the National Institutes of Health (NIH) score, the Disease Extent Index in TAK (DEI.TAK) and the Indian TAK Clinical Activity Score (ITAS2010) inconsistently associate with acute phase reactants (APRs). Computerized tomographic angiography (CTA), magnetic resonance angiography (MRA), or color Doppler Ultrasound (CDUS) enables anatomical characterization of stenosis, dilatation, and vessel wall characteristics. Vascular wall uptake of 18-fluorodeoxyglucose or other ligands using positron emission tomography computerized tomography (PET-CT) helps assess metabolic activity, which reflects disease activity well in a subset of TAK with normal APRs. Angiographic scoring systems to quantitate the extent of vascular involvement in TAK have been developed recently. Erythrocyte sedimentation rate and C-reactive protein have a moderate performance in distinguishing active TAK. Numerous novel biomarkers are under evaluation in TAK. Limited literature suggests a better assessment of active disease by combining APRs, PET-CT, and circulating biomarkers. Validated damage indices and patient-reported outcome measures specific to TAK are lacking. Few biomarkers have been evaluated to reflect vascular damage in TAK and constitute important research agenda.

show abstract

Section: Clinical Assessment Of Disease Activity and Damagementioning

confidence: 99%

Section: Clinical Assessment Of Disease Activity and Damagementioning

confidence: 99%

Section: Clinical Assessment Of Disease Activity and Damagementioning

confidence: 99%

Section: Clinical Assessment Of Disease Activity and Damagementioning

confidence: 99%

See 2 more Smart Citations

Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Takayasu arteritis) are lacking, identifying areas for future research. 70 However, strategies to improve PRO collection and use in rheumatology care are underway as part of the Rheumatology Informatics System for Effectiveness Learning Collaborative (RISE LC) initiative. 71 …”

Section: Patient-reported Outcome Data and Self-assessmentmentioning

confidence: 99%

Future challenges in rheumatology – is telemedicine the solution?

Thurah

Marques

Souza

et al. 2022

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

The COVID-19 pandemic has become an unprecedented facilitator of rapid telehealth expansion within rheumatology. Due to demographic shifts and workforce shortages in the future, new models of rheumatology care will be expected to emerge, with a growing footprint of telehealth interventions. Telehealth is already being used to monitor patients with rheumatic diseases and initial studies show good results in terms of safety and disease progression. It is being used as a tool for appointment prioritization and triage, and there is good evidence for using telehealth in rehabilitation, patient education and self-management interventions. Electronic patient-reported outcomes (ePROs) offer a number of long-term benefits and opportunities, and a routine collection of ePROs also facilitates epidemiological research that can inform future healthcare delivery. Telehealth solutions should be developed in close collaboration with all stakeholders, and the option of a telehealth visit must not deprive patients of the possibility to make use of a conventional ‘face-to-face’ visit. Future studies should especially focus on optimal models for rheumatology healthcare delivery to patients living in remote areas who are unable to use or access computer technology, and other patient groups at risk for disparity due to technical inequity and lack of knowledge.

show abstract